SPOM Provides a Shareholder Update
Press Release | 12/14/2021
On the morning of November 24, 2021, Mr. Lu Fengyou, CEO of SPOM Global, and Li Xingang, former dean of Qilu Hospital of Shandong University, reached an agreement with the intention to establish the development of the Shandong University Institute of Brain, and Brain Science (Jiaozhou). Sperson Medical Group, Canadian Bethune Institute of Encephalopathy and Shandong University Institute of Brain and Brain Science, intend to build a World-Class Research & Industry Incubator in Qingdao, focusing on stroke Basic Medicine, Clinical Treatment, Rehabilitation Intelligent Technology and Drug Research and Development, A three-tier industrial system will be built with core industry service facilities and medical rehabilitation facilities. Relying on the 3+2+1+1 industrial system, build 3 centers (Stroke Rehabilitation Technology and Drug Research Center, Health Management high-end Service Center, Stroke Treatment Center), 2 bases (Stroke Rehabilitation Base, Talent Training Base), 1 Center (Stroke International Symposium), 1 station (Stroke Academician Workstation).
Sperson Medical Group and Qingdao Xingyuan Real Estate Group selected the site in the Northeastern part of Jiaozhou City (Xingyuan-Paris City). This project is the core project of Qingdao Shanghe Demonstration Zone. Establish the Stroke Treatment and Rehabilitation Center of Shandong University's Institute of Brain and Brain Sciences, and plan to invest in a world-class stroke screening treatment and rehabilitation center, covering an area of 100 acres, with an investment of 700 million yuan, 300 treatment beds, and 500 rehabilitation beds. At the same time, in cooperation with Qingdao Health Construction Committee, it is planned to build 1,000 community screening and rehabilitation centers and medical consortiums; at the same time, it will establish the Shandong regional management headquarters and supporting businesses of Sperson.
As a professional medical management institution in Canada, Sperson Medical Group, after more than ten years of exploration in stroke screening, treatment and rehabilitation, has formed: precise acquisition of the source of disease, precise screening, precise cell therapy, precise interventional treatment, and precision The Symptomatic Rehabilitation & Precise Secret Recipe is a full-course therapy for Dorcen, which is the 6 major precision therapies for the treatment. The clinical effective rate of this therapy is over 80%, and it is in a leading position in the world.
The sincere cooperation between the two parties is bound to have a profound impact on the stroke industry and have a major boost to Shandong's medical market and even China.
SPO Global Inc. (OTC Pink: SPOM): SPO Global Inc. recently engaged with DB Capital M&A LLC., a Florida Company, and is currently working with the Companys Principal in regards to the Companys Corporate Development and Corporate Structure. SPO Global Inc. is working directly with a State-side Financial Institution in addition to working directly with DB Capital M&A LLC. SPO Global Inc. and its Management plans to focus on creating a better line of communication with its Shareholders. DB Capital M&A LLC., will be utilizing its expertise and contacts to assist SPOM in accomplishing its long-term goals. When an Agreement is met, the Company will update its Shareholders accordingly.
Company Disclaimers: As a Public Traded Company, within the guidlines of Federal and State Securities Law, SPO Global, Inc. may not avail itself of the Safe Harbor provisions as identified in the Private Securities Litigation Reform Act of 1995. However, SPO Global, Inc. provides the following disclaimer and warning to protect our shareholders, prospective investors and the public at large by alerting them to the risks and uncertainties involved with any investment, and the need to perform their own due diligence and assessment.
Forward-Looking Statements: This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the Company's business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company's periodic filings with the Securities and Exchange Commission.
Company Contact: fengyoulu@gmail.com
Source: SPO Global Inc.
